Pharmstandard was a partner of the III Far Eastern scientific and practical conference “Pacific Frontier. Modern ophthalmology”.

The prestigious forum took place in Vladivostok at the Pacific State Medical University, drawing nearly 300 participants from across Russia and 60 international experts.

The conference served as a platform for demonstrating cutting-edge equipment, innovative technologies, and analysing current practices and trends in drug therapy for eye diseases. Participants highly praised the forum’s contribution to advancing ophthalmic science and clinical practice. They emphasised that the knowledge gained, the opportunity to exchange best practices, and the professional connections established open up new avenues for further enhancing the quality of medical care. 

Pharmstandard is actively developing the production of medicinal products for the treatment of eye diseases that are in high demand by the healthcare system.

The group of companies’ product portfolio includes a wide range of medicinal products, including first-line therapies indicated for long-term or lifelong use in patients with ophthalmic diseases.

According to the company’s own estimates, its products Emoxipine (INN Methylethylpyridinol) and Latanoprost-Optic (INN Latanoprost), manufactured at Pharmstandard Group’s manufacturing sites, are market leaders, holding volume sales shares of 76% and 36.7% respectively, based on the results of the first nine months of 2025. Brand sales are demonstrating an upward trend*. These figures indicate a growing level of demand for medicinal products on the market.

High consumer activity is a sign of trust in the quality and safety of products. For patients, this is a guarantee that they are receiving proven products that meet modern medical standards.

Photo source: Website of the Pacific State Medical University

*According to analytical data from Pharmstandard, Retail sales channel, for 8 months. MAT 2024–2025.